Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 76 - 100 of 2667 in total

Salicylic acid

A compound obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics.
Approved
Investigational
Vet approved
Matched Mixtures name: … Neutrogena T/Gel Therapeutic ... System Acne Therapeutic System ... System Acne Therapeutic System …
Matched Products: … Therapeutic Dandruff ... Therapeutic Hydrogel ... Glovers Therapeutic Care …

Thrombomodulin Alfa

Thrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism.
Approved
Investigational
Matched Description: … Thrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). ... It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential …

Casirivimab

Casirivimab is a monoclonal antibody combined with Imdevimab in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. This drug is a combination of antibodies derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19. These antibodies have been formulated to...
Approved
Experimental
Matched Description: … Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this ... A224429] These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein …

Pegloticase

Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies. Pegloticase has a similar activity to rasburicase, an enzyme that metabolizes uric acid to allantoin. In gout patients treated with pegloticase, the conversion of...
Approved
Investigational
Matched Description: … Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in ... Therefore therapeutic drug levels can be maintained with infrequent and relatively low pegloticase doses …
Matched Categories: … Recombinant Proteins …

Benzoyl peroxide

Benzoyl peroxide is a commonly used drug in topical treatments for acne.[L33249,L33264,L33269,L33299,L33314] It has been formulated as products with either a single active ingredient,[L33249,L33299] or with erythromycin, clindamycin, or adapalene. After administration, the peroxide bond is cleaved, allowing benzoyloxy radicals to nonspecifically interact with proteins.[A18903,A233859] This treatment decreases keratin and...
Approved
Matched Mixtures name: … System Acne Therapeutic System ... System Acne Therapeutic System ... Clenziderm Normal To Oily Skin Acne Therapeutic System …
Matched Products: … Clenziderm Therapeutic ... Clenziderm Acne Therapeutic System …

Human C1-esterase inhibitor

C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a...
Approved

Bamlanivimab

Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19.[A224039, L15311, L15316] Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein, which is described to...
Approved
Investigational
Matched Description: … L15311, L15316] Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein …

Sirolimus

Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor...
Approved
Investigational
Matched Description: … kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target ... is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein …
Matched Categories: … Protein Kinase Inhibitors ... Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index …

Netilmicin

Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect...
Approved
Investigational
Matched Description: … Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal …
Matched Categories: … Protein Synthesis Inhibitors ... Narrow Therapeutic Index Drugs ... Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index …

Rivaroxaban

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15...
Approved

Calcium threonate

Calcium threonate is a calcium salt of threnoic acid and a novel drug developed for the treatment of osteoporosis and as a calcium supplement . It is found in dietary supplements as a source of L-threonate used in the treatment of calcium deficiency and prevention of osteoporosis. The most common...
Approved
Matched Description: … Therapeutic efficacy of calcium threonate in reducing was studied and investigated due to the hypothesis …

Benzoin

Benzoin is a white crystalline compound prepared by condensation of benzaldehyde in potassium cyanide, and is used in organic syntheses. This should not be confused with benzoin gum from STYRAX (see DB11222). Benzoin is an FDA-approved colour additive used for marking fruits and vegetables.
Approved
Experimental

Iodoform

Iodoform is an organoiodine compound with the formula CHI3 and a tetrahedral molecular geometry. It is a relatively water-insoluble yellow solid that is chemically reactive in free-radical reactions . Due to its antimicrobial properties following topical administration, minimal levels of iodoform may be found in disinfectants and it is more...
Approved
Experimental
Vet approved

Phenytoin

Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as...
Approved
Vet approved
Matched Description: … Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one ... phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal ... [A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require …
Matched Categories: … Narrow Therapeutic Index Drugs ... UGT1A1 Substrates with a Narrow Therapeutic Index ... UGT1A6 Substrates with a Narrow Therapeutic Index ... UGT1A9 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index …

Olipudase alfa

Olipudase alfa is recombinant human acid sphingomyelinase. It is the first and only enzyme replacement therapy in the world for the treatment of Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann–Pick disease. ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency...
Approved
Investigational
Matched Description: … Olipudase alfa is recombinant human acid sphingomyelinase. …
Matched Categories: … Recombinant Proteins …

Omacetaxine mepesuccinate

Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate...
Approved
Investigational
Matched Description: … Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein …
Matched Categories: … Protein Synthesis Inhibitors ... Narrow Therapeutic Index Drugs …

Entrectinib

Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's...
Approved
Investigational
Matched Description: … Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein …
Matched Categories: … Protein Kinase Inhibitors ... Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Ponatinib

Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Approved
Investigational
Matched Categories: … Protein Kinase Inhibitors ... Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …

Ceritinib

Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like...
Approved
Matched Description: … Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation ... of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. ... chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like …
Matched Categories: … Protein Kinase Inhibitors ... Narrow Therapeutic Index Drugs ... Receptor Protein-Tyrosine Kinases, antagonists & inhibitors ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Zanubrutinib

Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK...
Approved
Investigational
Matched Categories: … Protein Kinase Inhibitors ... Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Nuvaxovid

SARS-CoV-2, the causative agent of COVID-19, relies on the interaction between its trimeric spike (S) glycoprotein and angiotensin-converting enzyme 2 (hACE2) expressed on host cells in order to establish a productive infection in humans. Antibodies directed against the S protein are capable of blocking S-hACE2 interactions and neutralizing viral particles...
Approved
Investigational
Matched Description: … Nuvaxovid (NVX-CoV2373) contains a recombinant mutant S protein that is codon-optimized for baculovirus-mediated ... [A243789] Antibodies directed against the S protein are capable of blocking S-hACE2 interactions and ... [A243789, L39534] The resulting stable perfusion S protein nanoparticles are thermostable and capable …

Alectinib

Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK...
Approved
Investigational
Matched Description: … 4) fusion protein that causes proliferation of NSCLC cells. ... treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like …
Matched Categories: … Protein Kinase Inhibitors ... Narrow Therapeutic Index Drugs ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Pozelimab

CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US. The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement...
Approved
Investigational
Matched Description: … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease ... [L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein ... Pozelimab is a human, monoclonal immunoglobulin G4P antibody against the terminal complement protein …

Nadofaragene firadenovec

Nadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFNα2b). It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without...
Approved
Investigational
Matched Description: … Nadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus ... The use of nadofaragene firadenovec provides a therapeutic alternative to patients seeking non-surgical …
Matched Categories: … Recombinant Proteins …

Turmeric

Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental
Investigational
Matched Mixtures name: … Bee Venom Specialized Therapeutic …
Displaying drugs 76 - 100 of 2667 in total